In the clinical workup of AD patients CSF biomarkers amyloid-ß 1–42 (Aß42), total-tau (t-tau), and phosphorylated tau-181 (p-tau) are commonly assessed. The gene discussed is MAPT; the disease is Alzheimer disease.